Soleno Therapeutics reports Q4 EPS 80c vs. ($1.27) last year

Reports Q4 revenue $91.73M, consensus $88.55M. “Our first year as a commercial organization has been an outstanding success,” stated Anish Bhatnagar, chairman and CEO of Soleno Therapeutics (SLNO). “In just nine months, we received patient start forms representing over 12% of the U.S. VYKAT XR addressable market, reflecting both the strength of our world-class commercial team as well as the substantial disease burden that is addressed by VYKAT XR. We are very pleased with the positive trajectory of our other leading indicators, including patient start forms, patients on active therapy, unique prescribers, and lives covered.”